Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: A prospective pilot study

Stroke

Volumn 42, Issue 5, 2011, Pages 1301-1306

  Muehlschlegel, Susanne ^a   Rordorf, Guy ^b   Sims, John ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Department of Neurology   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

calcium; cerebral vasospasm; dantrolene; neurocritical care; ryanodine receptor; subarachnoid hemorrhage; vasoconstriction

Indexed keywords

DANTROLENE; LIVER ENZYME;

ADULT; ARTERIAL GAS; ARTICLE; BRAIN VASOSPASM; CLINICAL ARTICLE; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERUM OSMOLALITY; SINGLE DRUG DOSE; SUBARACHNOID HEMORRHAGE;

ADULT; BLOOD PRESSURE; DANTROLENE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; PILOT PROJECTS; PROSPECTIVE STUDIES; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL; VASOCONSTRICTION; VASOSPASM, INTRACRANIAL;

EID: 79955477320     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.603159     Document Type: Article

References (28)

1. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and func-tional outcome after subarachnoid hemorrhage: a systematic review. Stroke. 1997;28:660-664. (Pubitemid 27118394)
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Stein-berger J, Thom T, Wilson M, Hong Y, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
3. Bederson JB, Connolly ES Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, Duldner JE Jr, Harbaugh RE, Patel AB, Rosenwasser RH, American Heart Association. Guidelines for the management of aneurysmal sub-arachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40:994-1025.
4. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm fol-lowing aneurysmal subarachnoid hemorrhage. Stroke. 1985;16:562-572. (Pubitemid 15007226)
5. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, Wu YC, Klebanoff LM, Raps EC, Solomon RA. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a ran-domized controlled trial. Stroke. 2000;31:383-391. (Pubitemid 30078170)
6. Oropello JM, Weiner L, Benjamin E. Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage. Is it efficacious? No. Crit Care Clin. 1996;12:709-730. (Pubitemid 26256476)
7. Kato K, Tomura N, Takahashi S, Sakuma I, Watarai J. Ischemic lesions related to cerebral angiography: Evaluation by diffusion weighted MR imaging. Neuroradiology. 2003;45:39-43. (Pubitemid 36700814)
8. Tani E, Matsumoto T. Continuous elevation of intracellular Ca2+ is essential for the development of cerebral vasospasm. Curr Vasc Pharmacol. 2004;2:13-21. (Pubitemid 38855011)
9. Yamaura I, Tani E, Saido TC, Suzuki K, Minami N, Maeda Y. Calpain-calpastatin system of canine basilar artery in vasospasm. J Neurosurg. 1993;79:537-543. (Pubitemid 23289811)
10. Sato M, Tani E, Matsumoto T, Fujikawa H, Imajoh-Ohmi S. Generation of the catalytic fragment of protein kinase C alpha in spastic canine basilar artery. J Neurosurg. 1997;87:752-756. (Pubitemid 27454595)
11. Williams DA, Becker PL, Fay FS. Regional changes in calcium underlying contraction of single smooth muscle cells. Science. 1987;235: 1644-1648.
12. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR. Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308:619-624. (Pubitemid 13152325)
13. Linfante I, Delgado-Mederos R, Andreone V, Gounis M, Hendricks L, Wakhloo AK. Angiographic and hemodynamic effect of high concen-tration of intra-arterial nicardipine in cerebral vasospasm. Neurosurgery. 2008;63:1080-1086; discussion 1086-1087.
14. Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyper-thermia. Anesthesiology. 1982;56:254-262.
15. Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S. Neuroleptic malignant syndrome: Successful treatment with dantrolene and bromocriptine. Ann Neurol. 1983;14:89-90. (Pubitemid 13070079)
16. Frandsen A, Schousboe A. Dantrolene prevents glutamate cytotoxicity and Ca2 + release from intracellular stores in cultured cerebral cortical neurons. J Neurochem. 1991;56:1075-1078. (Pubitemid 21922725)
17. Zhang L, Andou Y, Masuda S, Mitani A, Kataoka K. Dantrolene protects against ischemic, delayed neuronal death in gerbil brain. Neurosci Lett. 1993;158:105-108. (Pubitemid 23261794)
18. Yano T, Nakayama R, Imaizumi T, Terasaki H, Ushijima K. Dantrolene ameliorates delayed cell death and concomitant DNA fragmentation in the rat hippocampal CA1 neurons subjected to mild ischemia. Resuscitation. 2001; 50:117-125. (Pubitemid 32727307)
19. Li F, Hayashi T, Jin G, Deguchi K, Nagotani S, Nagano I, Shoji M, Chan PH, Abe K. The protective effect of dantrolene on ischemic neuronal cell death is associated with reduced expression of endoplasmic reticulum stress markers. Brain Res. 2005;1048:59-68. (Pubitemid 40800260)
20. Muehlschlegel S, Sims JR. Dantrolene: mechanisms ofneuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit Care. 2009;10:103-115.
21. Salomone S, Soydan G, Moskowitz MA, Sims JR. Inhibition ofcerebral vasoconstriction by dantrolene and nimodipine. Neurocrit Care. 2009;10: 93-102.
22. Muehlschlegel S, Rordorf G, Bodock M, Sims JR. Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series. Neurocrit Care. 2009;10:116-121.
23. Fraser JF, Stieg PE. Hyponatremia in the neurosurgical patient: Epide-miology, pathophysiology, diagnosis, and management. Neurosurgery. 2006;59:222-229.
24. Flewellen EH, Nelson TE, Jones WP, Arens JF, Wagner DL. Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology. 1983;59:275-280. (Pubitemid 13012514)
25. Lindegaard KF, Nornes H, Bakke SJ, Sorteberg W, Nakstad P. Cerebral vasospasm diagnosis by means of angiography and blood velocity mea-surements. Acta Neuro. 1989;100:12-24. (Pubitemid 19247138)
26. Suarez JI, Qureshi AI, Yahia AB, Parekh PD, Tamargo RJ, Williams MA, Ulatowski JA, Hanley DF, Razumovsky AY. Symptomatic vasospasm diagnosis after subarachnoid hemorrhage: evaluation of transcranial Doppler ultrasound and cerebral angiography as related to compromised vascular distribution. Crit Care Med. 2002;30:1348-1355. (Pubitemid 34620983)
27. Lietman PS, Haslam RH, Walcher JR. Pharmacology of dantrolene sodium in children. Arch Phys Med Rehabil. 1974;55:388-392.
28. Freysz M, Timour Q, Bernaud C, Bertrix L, Faucon G. Cardiac impli-cations of amlodipine-dantrolene combinations. Can J Anaesth. 1996;43: 50-55.